At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Panitumumab + TAS-102drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With RAS (KRAS, NRAS) Wild-type, Unresectable, Advanced/Recurrent Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Panitumumab + TAS-102 for Colorectal Cancer. Completed, enrolled 56 participants across 32 sites.
Detailed Summary
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan and angiogenesis inhibitors).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2015
Primary CompletionOct 2017
Study CompletionMar 2018
TodayJul 2026
First PostedNov 24, 2015
Enrollment StartDec 7, 2015
Primary CompletionOct 6, 2017
Study CompletionMar 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.6 years ago
Interventions
Panitumumab + TAS-102drug
panitumumab + TAS-102 combination therapy